Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec 5;2013(12):CD005218.
doi: 10.1002/14651858.CD005218.pub4.

Spermicide used alone for contraception

David A Grimes  1 , Laureen M Lopez, Elizabeth G Raymond, Vera Halpern, Kavita Nanda, Kenneth F Schulz
Affiliations

Spermicide used alone for contraception

David A Grimes et al. Cochrane Database Syst Rev. .

Abstract

Background: Spermicides have been used as contraceptives for thousands of years. Despite this long use, only recently have studies examined the comparative efficacy and acceptability of these vaginal medications. Spermicides contain an active ingredient (most commonly nonoxynol-9) and a formulation used to disperse the product, such as foam or vaginal suppository.

Objectives: This review examined all known randomized controlled trials of a spermicide used alone for contraception.

Search methods: In August 2013, we searched the following computerized databases for randomized controlled trials of spermicides for contraception: CENTRAL, MEDLINE, POPLINE, LILACS, EMBASE, ClinicalTrials.gov, and ICTRP. For the initial review, we examined the reference lists of trials found as well as those of review articles and textbook chapters.

Selection criteria: We included any trial of a commercial product used alone for contraception. Each included trial must have provided sufficient information to determine pregnancy rates.

Data collection and analysis: Two authors independently extracted information from the trials identified. We did not conduct a meta-analysis, since most trials had large losses to follow up. We entered the data into tables and presented the results descriptively.

Main results: We located reports from 14 trials for the initial review, but have not identified any new trials since then. In the largest trial to date, the gel (Advantage S) containing the lowest dose of nonoxynol-9 (52.5 mg) was significantly less effective in preventing pregnancy than were gels with higher doses of the same agent (100 mg and 150 mg). Probabilities of pregnancy by six months were 22% for the 52.5 mg gel, 16% for the 100 mg dose, and 14% for the 150 mg dose. In the same trial, the three different vehicles with 100 mg of nonoxynol-9 had similar efficacy. Interpretation of these figures is limited, since 39% of participants discontinued the method or were lost from the trial. Few important differences in efficacy emerged in other trials.

Authors' conclusions: The probability of pregnancy varied widely in reported trials. A gel containing nonoxynol-9 52.5 mg was inferior to two other products tested in the largest trial. Aside from this finding, personal characteristics and behavior of users may be more important than characteristics of the spermicide products in determining the probability of pregnancy. Gel was liked more than the film or vaginal suppository in the largest trial. Spermicide trials have the dual challenges of difficult recruitment and high discontinuation rates; the latter threatens trial validity.

PubMed Disclaimer

Conflict of interest statement

DA Grimes has consulted with the pharmaceutical companies Bayer Healthcare Pharmaceuticals and Merck & Co, Inc.

EG Raymond conducted two of the included trials.

Update of

Similar articles

See all similar articles

References

References to studies included in this review

Abdelsalaam 1984 {unpublished data only}
    1. Family Health International for Abdelsalaam A. A comparative study of Neo Sampoon tablets versus Emko tablets in Zagazig, Egypt. Unpublished report, Family Health International, May 1984.
Andolsek 1988 {unpublished data only}
    1. Family Health International for Andolsek L. A comparative clinical trial of Neo Sampoon vaginal tablets and Emko vaginal foam in Ljubljana, Yugoslavia. Unpublished report, Family Health International, April 1988.
Chi 1987 {published and unpublished data}
    1. Chi I‐c, Smith SC, Borko E, Sun T‐H, Begum SF, Hunt WL, et al. Clinical acceptability, use patterns and use‐effectiveness of the vaginal contraceptive sponge and Neo Sampoon tablets ‐ an international multi‐center randomized clinical trial. Contraception 1987;36(36):499‐514. - PubMed
Chompootaweep 1990 {published data only}
    1. Chompootaweep S, Dusitin N. A comparative study of the safety, effectiveness and acceptability of two foaming vaginal tablets (nonoxynol‐9 versus menfegol) in Thai women. Contraception 1990;41(5):507‐17. - PubMed
Ghunney 1987 {unpublished data only}
    1. Family Health International for Ghunney E. Evaluation of the safety, effectiveness and acceptability of Ortho foaming vaginal tablets containing nonoxynol‐9 versus Ortho foaming tablets containing menfegol at a clinic in Accra, Ghana. Unpublished report, Family Health International, December 1987.
Kazi 1992 {unpublished data only}
    1. Family Health International for Kazi A. A comparative study of two foaming vaginal tablets for female barrier contraception in Pakistan. Unpublished report, Family Health International, September 1992.
Klufio 1988 {unpublished data only}
    1. Family Health International for Klufio C. Evaluation of the safety, effectiveness and acceptability of Ortho contraceptive foaming vaginal tablets containing nonoxynol‐9 versus Ortho contraceptive foaming tablets containing menfegol at a hospital in Accra, Ghana. Unpublished report, Family Health International, February 1988.
Lamptey 1985 {published and unpublished data}
    1. Lamptey P, Klufio C, Smith SC, Feldblum PJ. A comparative study of Neo Sampoon, Ortho vaginal tablets and Emko vaginal tablets in Accra, Ghana. Contraception 1985;32(5):445‐54. - PubMed
Poindexter 1984 {unpublished data only}
    1. Family Health International for Poindexter A III. A comparative study of Emko and Ortho vaginal tablets in Houston, Texas. Unpublished report, Family Health International, August 1984.
Raymond 1999 {published and unpublished data}
    1. Raymond E, Dominik R, the spermicide trial group. Contraceptive effectiveness of two spermicides: a randomized trial. Obstetrics and Gynecology 1999;93(6):896‐903. - PubMed
    1. Raymond EG, Alvarado G, Ledesma L, Diaz S, Bassol S, Morales E, et al. Acceptability of two spermicides in five countries. Contraception 1999;60(1):45‐50. - PubMed
Raymond 2004 {published and unpublished data}
    1. Raymond E, Chen PL, Pierre Louis B, Luoto J, Barnhart K, Bradley L, et al. Participant characteristics associated with withdrawal from a large randomized trial of spermicide effectiveness. BMC Medical Research Methodology 2004;4(1):23. [DOI: 10.1186/1471/-2288-4-23] - DOI - PMC - PubMed
    1. Raymond EG, Chen PL, Condon S, Luoto J, Barnhart KT, Bradley L, et al. Acceptability of five nonoxynol‐9 spermicides. Contraception 2005;71(6):438‐42. - PMC - PubMed
    1. Raymond EG, Chen PL, Luoto J, for the spermicide trial group. Contraceptive effectiveness and safety of five nonoxynol‐9 spermicides: a randomized trial. Obstetrics and Gynecology 2004;103(3):430‐9. - PubMed
Ruoff 1988 {unpublished data only}
    1. Family Health International for Ruoff G, Niland N, Halki J. Evaluation of the safety, effectiveness and acceptability of Ortho contraceptive foaming vaginal tablets containing nonoxynol‐9 versus Ortho contraceptive foaming vaginal tablets containing menfegol at three U.S. sites. Unpublished report, Family Health International, February 1988.
Younis 1985 {unpublished data only}
    1. Family Health International for Younis N. A comparative clinical trial of Emko and Ortho vaginal tablets in Cairo, Egypt. Unpublished report, Family Health International, October 1985.
Youssef 1987 {published data only}
    1. Youssef H, Crofton VA, Smith SC, Siemens AJ. A clinical trial of Neo Sampoon vaginal tablets and Emko foam in Alexandria, Egypt. Contraception 1987;35(2):101‐10. - PubMed

References to studies excluded from this review

Borko 1985 {published data only}
    1. Borko E, McIntyre SL, Feldblum PJ. A comparative clinical trial of the contraceptive sponge and Neo Sampoon tablets. Obstetrics and Gynecology 1985;65(4):511‐5. - PubMed
Burke 2010 {published data only}
    1. Blithe DL. Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®. http://clinicaltrials.gov/ct2/show/NCT00274261 (accessed 01 Aug 2013). [NCT00274261]
    1. Burke AE, Barnhart K, Jensen JT, Creinin MD, Walsh TL, Wan LS, et al. Contraceptive efficacy, acceptability, and safety of C31G and nonoxynol‐9 spermicidal gels: a randomized controlled trial. Obstetrics and Gynecology. 2010/11/26 2010; Vol. 116, issue 6:1265‐73. - PMC - PubMed
Steiner 1998 {published data only}
    1. Steiner MJ, Hertz‐Picciotto I, Schulz KF, Sangi‐Haghpeykar H, Earle BB, Trussell J. Measuring true contraceptive efficacy. A randomized approach‐‐condom vs. spermicide vs. no method. Contraception. 1999/03/30 1998; Vol. 58, issue 6:375‐8. - PubMed
Xu 2003 {published data only}
    1. Xu JX, Shi LT, Zhou XB, Xiao ZQ. Contraceptive efficacy of bioadhesive nonoxynol‐9 gel: comparison with nonoxynol‐9 suppository. Chinese Journal of Obstetrics and Gynecology 2003;38(10):629‐31. - PubMed
Xu 2006 {published data only}
    1. Xu JX, Huang ZR, Wu Y, Wang HY, Zhou XB, Xiao ZQ. [Contraceptive efficacy of bioadhesive benzalkonium chloride gel in comparison with nonoxynol‐9 gel]. Zhongua Fu Chan Ke Za Zhi 2006;41(10):706‐9. [NCT00692952] - PubMed

Additional references

Cates 2011
    1. Cates W Jr, Harwood B. Vaginal barriers and spermicides. In: Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Kowal D, Policar MS, et al. editor(s). Contraceptive Technology. 20th Edition. New York: Ardent Media, Inc., 2011:391‐408.
Connell 2002
    1. Connell EB. The contraception sourcebook. Chicago: Contemporary Books, 2002.
Embil 2005
    1. Embil Pharmaceutical Company. Spermicidal. www.embil.com/spermicidal.html (accessed 4 March 2005).
Roddy 1998
    1. Roddy R, Zekeng L, Ryan KA, Tamoufe U, Weir SS, Wong EL. A controlled trial of nonoxynol 9 film to reduce male‐to‐female transmission of sexually transmitted diseases. New England Journal of Medicine 1998;339(8):504‐10. - PubMed
Roddy 2002
    1. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Tweedy KG. Effect of nonoxynol‐9 gel on urogenital gonorrhea and chlamydial infection: a randomized controlled trial. Journal of the American Medical Association 2002;287(9):1117‐22. - PubMed
Scholes 2000
    1. Scholes D, Hooten TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. Risk factors for recurrent urinary tract infection in young women. Journal of Infectious Diseases 2000;182(4):1177‐82. - PubMed
Schulz 2002
    1. Schulz KF, Grimes DA. Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet 2002;359(9308):781‐5. - PubMed
Sherris 1984
    1. Sherris JD, Moore SH, Fox G. New developments in vaginal contraception. Population Reports 1984;XII:H‐157‐91.
Speroff 2001
    1. Speroff L, Darney PD. A Clinical Guide for Contraception. 3rd Edition. Philadephia, PA: Williams & Wilkins, 2001.
Steiner 2003
    1. Steiner MJ, Dalebout S, Condon S, Dominik R, Trussell J. Understanding risk: a randomized controlled trial of communicating contraceptive effectiveness. Obstetrics and Gynecology 2003;102(4):709‐17. - PubMed
Strauss 2005
    1. Strauss SE, Richardson WS, Glasziou P, Haynes RB. Evidence‐based Medicine: How to Practice and Teach EBM. Third Edition. New York: Churchill Livingstone, 2005.
Trussell 2011
    1. Trussell J. Contraceptive failure in the United States. Contraception 2011;83(5):397‐404. - PMC - PubMed
Van Damme 2002
    1. Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al. Effectiveness of COL‐1492, a nonoxynol‐9 vaginal gel, on HIV‐1 transmission in female sex workers: a randomised controlled trial. Lancet 2002;360(9338):971‐7. - PubMed
Vandebosch 2004
    1. Vandebosch A, Goetghebeur E, Ramjee G, Alary M, Ettiegne‐Traore V, Chandeying V, et al. Acceptability of COL‐1492, a vaginal gel, among sex workers in one Asian and three African cities. Sexually Transmitted Infections 2004;80(3):241‐3. - PMC - PubMed
WHO 2002
    1. World Health Organization. WHO/CONRAD technical consultation on nonoxynol‐9, World Health Organization, Geneva, 9‐10 October 2001: summary report. Reproductive Health Matters 2002;10(20):175‐81. - PubMed
WHO 2010
    1. World Health Organization. Medical eligibility criteria for contraceptive use. Fourth edition. http://whqlibdoc.who.int/publications/2010/9789241563888_eng.pdf. 3 (accessed 05 Aug 2013).
Zaneveld 1996
    1. Zaneveld LJD, Anderson DJ, Whaley KJ. Part 1. Barrier methods. In: Harrison P, Rosenfield A editor(s). Contraceptive research and development. Looking to the future. Washington, D.C.: National Academy Press, 1996:430‐45.

Publication types

MeSH terms

LinkOut - more resources